Our Services
Product Development

Planning and executing development programs across therapeutic areas and modalities, with a specialist, fractional CXO leadership, or a full virtual team.

Opportunity Mapping

Preclinical Strategy & Execution

Clinical Development

Clinical Operations & Trial Management

Regulatory Affairs

CMC Consulting

CDMO & CRO Selection & Management
Enterprise Development

The strategic and operational foundations to advance and fund your programs, from interim C-suite leadership to business planning and platform strategy.

Business Plans & Fundraising Support

Interim Chief Medical Officer

Virtual Biotech Support

Technology Platform Strategy

Launch Planning
Business Development

Buy-side and sell-side support for pharma, biotech, and investors, from asset scouting and due diligence through valuations, partnering, and deal close.

Due Diligence

Due Diligence Training

Valuations

In-Licensing & Asset Scouting

Out-Licensing, Partnering & Deal-making

Academic Commercialization
Investors and Law Firms

Scientific, strategic, and operational support across the investment lifecycle, and expert witnesses with the technical or commercial depth a case requires.

Investor Services

Expert Witness Services
View all services
Who We Serve
Organizations we work with
Also browse by
Disease Area

CNS

Digestive & GI

Endocrine & Metabolic

Fibrosis

Hematology

Immunology

Oncology

Respiratory

Other Disease Areas
Product Modality

Antibodies, ADCs

Cell Therapies

Drug Discovery Platforms

Gene Therapies

Microbiome Drugs

Peptides & Proteins

Radiopharmaceuticals

Small Molecules

Other Product Modalities
Our Company
Since 2009, Alacrita’s core team and associate consultants have supported biotechs, pharma companies, investors, and universities on development programs, deals, and company building, from Cambridge, MA and London.
More about Alacrita
Insights
View all insights

Latest

Whitepaper Deterministic Intelligence in a Probabilistic World The clinical record behind AI-derived drugs is smaller and more divided than its reputation. What regulators now require, and what these assets are ... Read whitepaper Article When AI Is Standard, Where Is the Edge in Drug Development? As AI becomes standard in drug development, where does competitive advantage lie? We examine clinical trial efficiency, asset selection, and ... Read article
More recent
Case Studies
Contact

Whitepapers

news and resources
Whitepapers

Anthony Walker, PhD, and Cort Hepler

Recent Posts

Deterministic Intelligence in a Probabilistic World

05th November 2026

Alacrita Whitepaper Deterministic Intelligence In brief The scorecard, late 2026 Two curves, one gap "Deterministic" has become a regulatory word Generate, then govern Clinical development: evidenced...

What Pharma Is Backing in Drug Discovery: A Field Guide

Contents Overview What's different today Wave 1: Validated Antibody-drug conjugates GLP-1 and incretin biology Radiopharmaceuticals Wave 2: Approaching inflection Targeted protein degradation Gene...

1

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

Strategy and Commercialization Learn more
Product Development Learn more
Business Development Learn more

© 2009-26 Alacrita Holdings Limited | Pharma & Biotech Consulting

Privacy Notice

Alacrita Consulting
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608

One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.